IL33 and gastric cancer: To evaluate the effect of p38 signaling pathway on tumor progression and macrophage polarization, we established a model of GC abdominal dissemination treated with IL-33 combined with p38 inhibitor (SB203580) and evaluated the anti-tumor efficacy of combined therapy (Fig. 7A).